Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) - The Eastern Cooperative Oncology Group (ECOG) Results

Avi I. Einzig*, Stuart Lipsitz, Peter H. Wiernik, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Taxol was administered as a 24-hour continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered between July 1991 and June 1992, twenty-three were eligible and were evaluated for toxicity and twenty-two were assessable for response. There was one partial response (4.5%) in a patient with liver metastases, with a duration of 6 months. Toxicity was primarily neutropenia. Taxol as a single agent appears to have little activity in adenocarcinoma of the UGIT.

Original languageEnglish (US)
Pages (from-to)223-227
Number of pages5
JournalInvestigational New Drugs
Volume13
Issue number3
DOIs
StatePublished - Sep 1 1995

    Fingerprint

Keywords

  • Taxol (paclitaxel)
  • upper gastrointestinal tumors

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this